Puma Biotechnology Inc (PBYI)
2.99
+0.02
(+0.67%)
USD |
NASDAQ |
Nov 14, 16:00
2.985
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Enterprise Value: 128.12M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 128.12M |
| November 13, 2024 | 127.14M |
| November 12, 2024 | 138.92M |
| November 11, 2024 | 143.34M |
| November 08, 2024 | 122.72M |
| November 07, 2024 | 130.09M |
| November 06, 2024 | 131.56M |
| November 05, 2024 | 126.65M |
| November 04, 2024 | 126.16M |
| November 01, 2024 | 126.10M |
| October 31, 2024 | 121.19M |
| October 30, 2024 | 120.70M |
| October 29, 2024 | 118.25M |
| October 28, 2024 | 120.21M |
| October 25, 2024 | 126.10M |
| October 24, 2024 | 118.74M |
| October 23, 2024 | 119.23M |
| October 22, 2024 | 120.70M |
| October 21, 2024 | 119.23M |
| October 18, 2024 | 122.66M |
| October 17, 2024 | 120.21M |
| October 16, 2024 | 122.66M |
| October 15, 2024 | 121.19M |
| October 14, 2024 | 121.19M |
| October 11, 2024 | 121.19M |
| Date | Value |
|---|---|
| October 10, 2024 | 114.32M |
| October 09, 2024 | 111.38M |
| October 08, 2024 | 109.91M |
| October 07, 2024 | 111.87M |
| October 04, 2024 | 111.38M |
| October 03, 2024 | 105.00M |
| October 02, 2024 | 102.06M |
| October 01, 2024 | 108.92M |
| September 30, 2024 | 106.47M |
| September 27, 2024 | 118.77M |
| September 26, 2024 | 117.79M |
| September 25, 2024 | 117.30M |
| September 24, 2024 | 117.30M |
| September 23, 2024 | 117.30M |
| September 20, 2024 | 119.75M |
| September 19, 2024 | 117.79M |
| September 18, 2024 | 114.85M |
| September 17, 2024 | 119.75M |
| September 16, 2024 | 115.83M |
| September 13, 2024 | 116.32M |
| September 12, 2024 | 115.34M |
| September 11, 2024 | 114.85M |
| September 10, 2024 | 109.45M |
| September 09, 2024 | 106.02M |
| September 06, 2024 | 102.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
97.23M
Minimum
May 11 2022
554.27M
Maximum
Feb 05 2020
251.91M
Average
219.32M
Median
Jan 02 2024
Enterprise Value Benchmarks
| Pfizer Inc | 204.39B |
| NovaBay Pharmaceuticals Inc | 2.833M |
| Palatin Technologies Inc | 11.39M |
| iBio Inc | 5.346M |
| Theriva Biologics Inc | -13.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.32M |
| Revenue (Quarterly) | 80.54M |
| Total Expenses (Quarterly) | 58.46M |
| EPS Diluted (Quarterly) | 0.41 |
| Gross Profit Margin (Quarterly) | 63.87% |
| Profit Margin (Quarterly) | 25.23% |
| Earnings Yield | 15.72% |
| Operating Earnings Yield | 22.38% |
| Normalized Earnings Yield | 15.72 |